Phase I Study of Intravenous PSC-833 and Doxorubicin: Reversal of Multidrug Resistance

Hironobu Minami,1, 4 Tomoko Ohtsu,1 Hirofumi Fuji,1 Tadahiko Igarashi,1 Kuniaki Itoh,1 Noriko Uchiyama-Kokubu,2 Tetsushi Aizawa,2 Toru Watanabe,2 Yoshinori Uda,2 Yusuke Tanigawara3 and Yasutsuna Sasaki1

1Division of Oncology/Hematology, Department of Medicine, National Cancer Center Hospital East, 2Tsukuba Research Institute, Novartis Pharma K.K., 3Department of Hospital Pharmacy, Keio University School of Medicine, 35 Shinano-machi, Shinjuku-ku, Tokyo 160-8582

PSC-833 reverses multidrug resistance by P-glycoprotein at concentrations ≤1000 ng/ml. A phase I study of PSC-833 and doxorubicin was conducted to determine the maximum tolerated dose and to investigate pharmacokinetics. PSC-833 was intravenously infused as a 2-h loading dose (LD) and a subsequent 24-h continuous dose (CD). Doxorubicin was infused over 5 min, 1 h after the LD. The starting dose was 1 mg/kg for both LD and CD with 30 mg/m² doxorubicin; these dosages were increased to 2 and 10 mg/kg and 50 mg/m², respectively. Thirty-one patients were treated. Nausea/vomiting was controllable with granisetron and dexamethasone. Neutropenia and ataxia were dose limiting. Steady-state concentrations of PSC-833 were achieved at a 2 mg/kg LD and a 10 mg/kg CD. Ex-vivo bioassay revealed that activity in serum for reversing multidrug resistance was achieved in all patients; IC50 of P-glycoprotein expressing 8226/Dox6 in patients' serum was decreased from 5.9 to 1.3 µg/ml (P<0.0001) by PSC-833 administration. Doxorubicin clearance was 24.3±13.7 (mean±SD) liter/h/m², which was lower than the 49.0±16.9 liter/h/m² without PSC-833 (P<0.0001). The relationship between doxorubicin exposure and neutropenia did not differ between patients treated and not treated with PSC-833. The recommended phase II dose of PSC-833 was 2 and 10 mg/kg for LD and CD, respectively, which achieved a sufficient concentration in serum to reverse drug resistance, as confirmed by bioassay. The dose of doxorubicin should be reduced to 40 mg/m², not because of the pharmacodynamic interaction between PSC-833 and doxorubicin affecting hematopoiesis, but because of pharmacokinetic interaction.

Key words:    PSC-833 — Doxorubicin — Pharmacokinetics — Pharmacodynamics — Multidrug resistance

Multidrug resistance is a phenomenon by which cancer cells show cross-resistance to various classes of anticancer agents including anthracyclines, vinca alkaloids, epipodophyllotoxins, paclitaxel, and irinotecan.1-3) P-Glycoprotein, a product of multiple drug resistance gene 1 (mdr-1), is responsible for a large part of multidrug resistance, and P-glycoprotein is expressed in clinical samples of tumors obtained from patients with a variety of malignancies, both treated and untreated with anticancer agents.1, 4) It is a membrane transporter and acts as an efflux pump that excretes various anticancer drugs from cancer cells. Inhibiting the function of P-glycoprotein may increase the sensitivity of cancer cells to anticancer agents and improve the efficacy of chemotherapy. P-Glycoprotein is also expressed in normal tissues, including the biliary canalicular membrane of hepatocytes and the brush-border membrane of renal tubular cells, and acts as an active efflux transporter excreting drugs into bile and urine.5) Furthermore, it is expressed in brain capillary endothelial cells and functions as a blood-brain barrier.6, 7) Therefore, P-glycoprotein is important not only in the resistance of cancer cells to anticancer agents, but also in the pharmacokinetics of the drugs.

In vitro and in vivo experiments showed that a variety of agents have activity to reverse the multidrug resistance of cancers. These agents include verapamil,8) nifedipine,9) quinidine,10) quinine,11) cyclosporin,12) tamoxifen,13) and toremifene.14) Among these P-glycoprotein inhibitors of the first generation, verapamil and cyclosporin were the most active and most often tested in clinical studies.2, 12, 15, 16) Although they showed some ability to abolish the function of P-glycoprotein in clinical studies, the results of these studies did not fulfill the promise of the preclinical data.13, 16) Multiplicity and redundancy of the resistance mechanisms of cancers might partly explain the disappointing results of these clinical studies, but the weak activity in reversing drug resistance and the toxicities of these drugs also might be responsible for the negative results.15, 17-19

PSC-833 ([3'-keto-Bmt1]-[Val2]-cyclosporin, valspodar) is a non-nephrotoxic and non-immunosuppressive deriva-
tive of cyclosporin D which can reverse the multidrug resistance caused by P-glycoprotein overexpression in vitro and in vivo. It was at least 10-fold more active than cyclosporin A on most P-glycoprotein-expressing tumor cell lines in vitro, and prolongation of survival times of mice bearing a multidrug-resistant tumor was documented in vivo.20,21) PSC-833 can completely inhibit P-glycoprotein of various cell lines in vitro at concentrations of 300 to 1000 ng/ml, and a target concentration of PSC-833 in clinical studies was considered to be 1000 ng/ml.20,21) Based on these data, clinical studies have been conducted using oral or intravenous administration of PSC-833 in combination with various anticancer agents.22–26) Patients could tolerate the target concentration in these studies, and activity in patients’ serum for reversing P-glycoprotein function was shown by the increased accumulation of daunorubicin in a P-glycoprotein-expressing cell line.24) However, a large fluctuation of PSC-833 concentration was observed in studies using oral administration, with trough levels far below the target concentration,22,26) and activity in patients’ serum to sensitize multidrug-resistant tumors has not yet been demonstrated. In this study, we conducted a phase I study of the intravenous infusion of PSC-833 in combination with doxorubicin to clarify the toxicity profile, to define the maximum-tolerated dose and the recommended dose, and to investigate the pharmacological profile of PSC-833 and doxorubicin in combination. We also demonstrated that serum of patients treated at the recommended dose of PSC-833 had sufficient activity to reverse the resistance to doxorubicin in a multidrug-resistant cancer cell line.

PATIENTS AND METHODS

Patients Eligibility criteria included patients with histologically or cytologically confirmed solid malignant tumors which were refractory to standard therapy or for which no effective therapy was available, who were 20 to 74 years of age, and had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of two or better. Prior chemotherapy and radiotherapy had to be completed at least 3 weeks (6 weeks for nitrosourea and mitomycin-C) before entry into the study, and the total field of prior radiotherapy should encompass less than a third of hematopoietic bones. Patients should have a life expectancy of ≥8 weeks and adequate organ function, with leukocyte count ≥4000/mm³ and <10 000/mm³, hemoglobin ≥10.0 g/dl, platelet count ≥100 000/mm³, creatinine ≤1.5 mg/dl, bilirubin ≤1.5 mg/dl, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2× normal, creatinine clearance ≥50 ml/min, PaO₂ ≥70 mmHg, normal electrocardiogram, and left ventricular ejection fraction ≥50% as determined by ultrasonography. Patients who had been treated with a cumulative doxorubicin dose of ≥300 mg/m² and patients with a history of significant cardiovascular diseases were ineligible. Patients with an active infection, brain or leptomeningeal involvement, pregnancy, or a past history of central nervous diseases were also excluded from the study.

This phase I study was conducted in accordance with guidelines by the Ministry of Health and Welfare, Japan. Written informed consent according to institutional and regulatory requirements was obtained from all patients and the study was approved by the Institutional Review Board (IRB) of the National Cancer Center, Japan.

Treatment PSC-833 was administered as an intravenous infusion. A loading dose of PSC-833 was infused over 2 h in 100 ml of normal saline followed immediately by a continuous dose infused over 24 h in 500 ml of normal saline. Doxorubicin was dissolved in 20 ml of saline and intravenously infused over 5 min beginning 1 h after the end of the loading dose (1 h into the infusion of the continuous dose). The treatment was repeated every 3 weeks until disease progression or intolerable toxicity was observed.

Dose escalation was started at 1 mg/kg both for the loading dose and the continuous dose of PSC-833 in combination with 30 mg/m² of doxorubicin. In the first part of the dose escalation, PSC-833 dosages were increased with a fixed dose of doxorubicin (Table I). After the continuous dose was increased to 10 mg/kg at dose level VI, at which the target PSC-833 concentration of 1000 ng/ml was achieved in all patients, the dose of doxorubicin was increased by 10 mg/m² to 50 mg/m² with fixed doses of PSC-833. At least three patients were treated at one dose level and the dose was increased if none experienced dose-limiting toxicity. When dose-limiting toxicity was observed in one of three patients, the dose level was expanded to six patients. The dose escalation was continued until the maximum-tolerated dose was achieved at the point where two of the first three patients or two of the six patients experienced dose-limiting toxicity. The dose-lim-

| Dose level | Loading dose (mg/kg) | Continuous dose (mg/m²) | Number of patients |
|------------|----------------------|-------------------------|-------------------|
| I          | 1                    | 1                       | 4                 |
| II         | 1                    | 2                       | 3                 |
| III        | 2                    | 4                       | 3                 |
| IV         | 2                    | 6                       | 6                 |
| V          | 2                    | 8                       | 7                 |
| VI         | 2                    | 10                      | 3                 |
| VII        | 2                    | 10                      | 4                 |
| VIII       | 2                    | 10                      | 2                 |
iting toxicities included grade 4 leukopenia and/or neutropenia lasting for 4 days or longer, grade 4 thrombocytopenia, and grade 3 or greater nonhematologic toxicity except for alopecia and hyperbilirubinemia. Hyperbilirubinemia was considered to be dose limiting when the serum bilirubin level was elevated to 10 mg/dl or higher. Intrapatient dose escalation was not performed.

Prophylactic anti-emetic drugs were not used until dose level IV. Three of the first four patients treated at dose level V developed grade 3 nausea or vomiting despite the prophylactic use of granisetron in two of those patients. Because of this observation, the protocol was amended to incorporate the intensive use of prophylactic anti-emetics. Granisetron 3 mg and dexamethasone were administered intravenously twice a day on days 1 and 2. The use of granisetron and dexamethasone on days 3 to 5 was left to the discretion of attending physicians.

Pharmacokinetics Blood sampling for determinations of pharmacokinetics of PSC-833 was conducted before and at the end of the loading dose infusion, at 1, 2, 4, 8, and 12 h into the continuous dose infusion, at the end of the continuous dose infusion, and 24 and 48 h after the end of infusion. For the pharmacokinetic study of doxorubicin, blood was drawn just before the administration of doxorubicin and 5 (end of infusion), 10, 20, and 35 min, and 1, 2, 3, 4, 7, 11, 23, 47 and 71 h after the start of the doxorubicin infusion. To investigate the effect of PSC-833 on doxorubicin pharmacokinetics, doxorubicin pharmacokinetics of study patients treated with PSC-833 were compared to those of control patients who did not receive PSC-833. The control patients were treated with doxorubicin as a single agent or in combination chemotherapy in a separate IRB-approved pharmacokinetic study. This control group consisted of 17 females and 9 males who were eligible for the phase I study of PSC-833 in combination with doxorubicin with regard to age, PS and hepatorenal function. Doxorubicin at doses ranging from 20 to 70 mg/m² was administered to the control patients by a 5-min infusion using the same schedule as the phase I study of PSC-833 and doxorubicin. Blood for studies of the pharmacokinetics of doxorubicin was obtained before doxorubicin administration, 5 (end of infusion), 15, and 30 min, and 1, 3, 4, 7, 24, 48 and 72 h after the beginning of the doxorubicin infusion.

PSC-833 concentrations in whole blood were determined using a radioimmunoassay kit (ANAWA Laboratorien AG, Zurich, Switzerland). The assay for doxorubicin and its metabolite, doxorubicinol, was conducted by using, with slight modification, a high-performance liquid chromatography method which was described previously. Pharmacokinetic analysis was performed using a non-compartment method. The elimination constant was calculated by linear regression of the terminal log-linear part of the time-concentration curves. However, the elimination constant of PSC-833 could not be determined due to the limited number of samples after the end of the infusion. The steady-state concentration of PSC-833 was calculated as the area under the time-concentration curve (AUC) from 1 h after the administration of doxorubicin to the last measured concentration of PSC-833 during the infusion divided by the time duration.

Pharmacodynamics For the pharmacodynamic analysis, the surviving fraction of neutrophils was calculated by dividing the neutrophil count at the nadir by the pretreatment count, and relationship between the AUC of doxorubicin and the surviving fraction was investigated. When the effect of the PSC-833 concentration on doxorubicin pharmacodynamics was evaluated, the relationship between the AUC of doxorubicin vs. the surviving fractions of neutrophils in the control patients treated with doxorubicin alone was compared to that of patients treated with doxorubicin and PSC-833.

Ex-vivo bioassay of activity for reversal of resistance The activity of patients’ serum in reversing the resistance to doxorubicin of a multidrug-resistant cell line was tested using an ex-vivo bioassay. For this purpose, blood was drawn before the PSC-833 infusion, just before the doxorubicin administration during the PSC-833 infusion, and at the end of the infusion of the continuous dose of PSC-833. The bioassay was performed using 8226/Dox, a doxorubicin-resistant cell line of human myeloma RPMI 8226.
Phase I Study of PSC-833 with Doxorubicin

8226,^29,30^ 8226/Dox^8^, and RPMI 8226 were kind gifts from Dr. William S. Dalton (University of Arizona Cancer Center, Tucson, AZ). The method for the bioassay has been described in detail elsewhere (Uchiyama-Kokubu, N. et al., in preparation). In brief, the cells were exposed to doxorubicin at various concentrations for 3 h in patients' serum. For the serum obtained at the end of the PSC-833 infusion, the amount of doxorubicin added to the serum was the difference between the plasma concentration of doxorubicin measured by HPLC and the final concentration required for the assay. We intended to perform the bioassay using whole serum, but the final serum concentration was 75% because of the volume of doxorubicin solution added. Cell-growth was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, and an IC\textsubscript{50} value reflecting the concentration of doxorubicin producing 50% inhibition of tumor growth was calculated. The activity for reversing doxorubicin resistance in patients’ serum during treatment with PSC-833 was expressed as the dose-modifying factor, which was calculated by dividing the IC\textsubscript{50} of doxorubicin in serum before the infusion of PSC-833 by the IC\textsubscript{50} in serum during the infusion.

**RESULTS**

**Toxicities** A total of 31 patients were treated with 75 courses of doxorubicin combined with PSC-833 (Table II). Before the entry into this study, all but two patients had received prior chemotherapy of 1 to 4 (median 2) regimens. Nineteen patients had received anthracyclines, and six other patients had been treated with other multidrug resistance-related anticancer agents, including vindesine and irinotecan.

At dose level V, grade 4 neutropenia was observed in three of seven patients, and a patient with carcinoma of the ampulla of Vater developed grade IV leukopenia, neutropenia and anemia complicated by liver abscess (Table III). This patient died from septic shock and disseminated intravascular coagulation 7 days after treatment. Neutropenia lasting for 4 days or longer was dose limiting in two patients treated at dose level VIII, which was deemed the maximum-tolerated dose. Thrombocytopenia was mild, and grade 3 thrombocytopenia was observed only in the patient who died from septic shock complicated by disseminated intravascular coagulation (Table III).

No grade 3 or greater nausea or vomiting was observed without prophylactic anti-emetics until dose level V, where three of the first four patients experienced grade 3 nausea or vomiting despite the prophylactic use of granisetron to granisetron (8 mg twice a day) and granisetron (3 mg twice a day), no grade 3 or worse nausea or vomiting was observed at any dose.

---

**Table II. Characteristics of Patients**

| Total number of patients | 31 |
|--------------------------|----|
| Sex (female/male)        | 16/15 |
| Age (median)             | 58 |
| (range)                  | 28–69 |
| PS (0/1/2)               | 7/21/3 |
| Diseases                 |    |
| Breast cancer            | 8  |
| Colorectal cancer        | 5  |
| Gastric cancer           | 2  |
| Non-small cell lung cancer | 2 |
| Ovarian cancer           | 2  |
| Others                   | 12 |
| Prior therapy            |    |
| Surgery                  | 22 |
| Radiotherapy             | 13 |
| Chemotherapy             | 29 |

**Table III. Hematological Toxicity**

| Dose level | No. patients | No. cycles |
|------------|--------------|------------|
| I          | 4            | 16         |
| II         | 3            | 3          |
| III        | 3            | 6          |
| IV         | 6            | 22         |
| V          | 7            | 11         |
| VI         | 3            | 4          |
| VII        | 3            | 6          |
| VIII       | 2            | 4          |

| Grade | Leukopenia | Neutropenia | Thrombocytopenia | Anemia |
|-------|------------|-------------|------------------|-------|
|       | 1 2 3 4    | 1 2 3 4     | 1 2 3 4          | 1 2 3 4 |
| I     |            |             |                  |       |
| II    |            |             |                  |       |
| III   |            |             |                  |       |
| IV    |            |             |                  |       |
| V     |            |             |                  |       |
| VI    |            |             |                  |       |
| VII   |            |             |                  |       |
| VIII  |            |             |                  |       |

a) Dose-limiting toxicity.

---

223
Table IV. Nonhematological Toxicity

| Dose level | No. patients | No. cycles | Grade | Nausea | Vomiting | Anorexia | Hyperbilirubinemia | Ataxia |
|------------|--------------|------------|--------|--------|----------|----------|-------------------|--------|
| I          | 4            | 16         | 1–VI   | 1–VI   | 1–VI     | 1–VI     | 1–VI              | 1–VI   |
| II         | 3            | 3          | 3–VI   | 3–VI   | 3–VI     | 3–VI     | 3–VI              | 3–VI   |
| III        | 3            | 6          | 4–VI   | 4–VI   | 4–VI     | 4–VI     | 4–VI              | 4–VI   |
| IV         | 6            | 22         | 5–VI   | 5–VI   | 5–VI     | 5–VI     | 5–VI              | 5–VI   |
| V          | 7            | 11         | 6–VI   | 6–VI   | 6–VI     | 6–VI     | 6–VI              | 6–VI   |
| VI         | 3            | 4          | 7–VI   | 7–VI   | 7–VI     | 7–VI     | 7–VI              | 7–VI   |
| VII        | 3            | 6          | VIII   | VIII   | VIII     | VIII     | VIII              | VIII   |

a) Dose-limiting toxicity.

Dose-limiting grade 3 ataxia was observed at dose level VIII. Although grade 4 hyperbilirubinemia was observed in the patient who died from biliary infection, hyperbilirubinemia was transient and clinically insignificant in the other patients. Usually it was not associated with an elevation of transaminases.

An asymptomatic decrease of the ejection fraction was documented in a patient treated at dose level IV. The ejection fraction in the patient was 64% before treatment and decreased to 58% after the first course and to 49% 2 weeks after the second course; this value then returned to 58% in 3 weeks.

Pharmacokinetics Time courses of the concentration of PSC-833, doxorubicin and doxorubicinol in a representative patient treated at dose level VII are shown in Fig. 1. A stable concentration of PSC-833 during infusion of the continuous dose was achieved.

Table V. Pharmacokinetic Parameters of Doxorubicin and Doxorubicinol

| Dose level | No. patients | LD (mg/kg) | CD (mg/kg) | Doxorubicin dose (mg/m²) | PSC-833 | Doxorubicin | Doxorubicinol | AUCₒ (ng×h/ml) | Half life (h) | Clearance (liter/h/m²) | Vₐₒ (liter/m²) | AUCₒ (ng×h/ml) | Half life (h) | AUCₒ/doxorubicin |
|------------|--------------|------------|------------|--------------------------|---------|-------------|--------------|----------------|--------------|----------------------|----------------|----------------|--------------|-------------------|
| I–VI       | 26           | 1–2        | 1–10       | 30                       | 1051±528 | 49.6±29.0 | 24.8±15.0 | 830±388 | 1236±509 | 35.0±15.2 | 1.3±0.5 | 34.7±10 | 1.4±0.6 | 1.1±0.5 |
| VII        | 3            | 2          | 10         | 40                       | 1197±54 | 51.8±1.8 | 24.4±1.2 | 1259±127 | 1946±1205 | 34.3±6.8 | 1.6±1.0 | 34.7±10 | 1.4±0.6 | 1.1±0.5 |
| VIII       | 2            | 2          | 10         | 50                       | 2207±425 | 41.7±0.4 | 18.5±3.5 | 727±150 | 4860±909 | 32.4±11.2 | 2.2±0.0 | 34.7±10 | 1.4±0.6 | 1.1±0.5 |
| Total      | 31           | 1           | 2          | 10                       | 40      | 1197±54 | 51.8±1.8 | 24.4±1.2 | 1259±127 | 1946±1205 | 34.3±6.8 | 1.6±1.0 | 34.7±10 | 1.4±0.6 | 1.1±0.5 |
| Control    | 2            | 0          | 0          | 20                       | 378±167 | 35.2±40.0 | 41.5±29.8 | 894±921 | 369±3 | 37.6±4.0 | 1.1±0.5 | 34.7±10 | 1.4±0.6 | 1.1±0.5 |
| Control    | 8            | 0          | 0          | 30                       | 479±171 | 19.2±13.5 | 56.0±24.3 | 536±190 | 363±194 | 47.9±5.0 | 1.1±0.5 | 34.7±10 | 1.4±0.6 | 1.1±0.5 |
| Control    | 3            | 0          | 0          | 40                       | 802±172 | 28.9±8.4 | 38.4±7.4 | 1016±225 | 660±104 | 34.5±5.1 | 0.9±0.2 | 34.7±10 | 1.4±0.6 | 0.9±0.2 |
| Control    | 9            | 0          | 0          | 50                       | 819±177 | 29.8±9.9 | 48.1±10.2 | 1242±453 | 676±213 | 41.9±5.1 | 0.9±0.2 | 34.7±10 | 1.4±0.6 | 0.9±0.2 |
| Control    | 4            | 0          | 0          | 70                       | 904±500 | 31.8±13.7 | 50.9±13.8 | 1346±376 | 1036±672 | 36.8±1.8 | 1.3±0.1 | 34.7±10 | 1.4±0.6 | 0.9±0.2 |
| Total      | 26           | 27.3±14.3 | 49.0±16.9 | 992±490 | 41.5±7.3 | 0.9±0.3 |

Parameters are mean value±SD.

a) LD, loading dose; b) CD, continuous dose; c) AUCₒ, area under the concentration-time curve to the last measured point; d) Vₐₒ, distribution volume at the steady state; e) AUCₒ/doxorubicin, the ratio of doxorubicinol AUCₒ to doxorubicin AUCₒ; f) data for 24 patients; g) data for 23 patients; h) data for 21 patients; i) data for 29 patients; j) data for 26 patients; k) data for 28 patients; l) data for 7 patients; m) data for 3 patients.
Pharmacokinetic parameters of doxorubicin and doxorubicinol are listed in Table V, together with control data (without PSC-833). Doxorubicin clearance in all patients treated with PSC-833 (24.3\(\pm\)13.7 liter/h/m\(^2\), mean\(\pm\)SD) was significantly lower than that in patients treated without PSC-833 (49.0\(\pm\)16.9 liter/h/m\(^2\), \(P<0.0001\) by Mann-Whitney U test). Accordingly, when the AUC of doxorubicin was compared among patients treated with the same dose (30 mg/m\(^2\)), the AUC of doxorubicin in the presence of PSC-833 was two times greater than that of controls (\(P=0.004\)). The relationship between the steady-state concentration of PSC-833 and the clearance of doxorubicin is shown in Fig. 2. The doxorubicin clearance of patients treated without PSC-833 is plotted on the ordinate line. The doxorubicin clearance was decreased when the PSC-833 concentration was increased to around 500 ng/ml.

The pharmacokinetic interaction between PSC-833 and dexamethasone was sought but no difference in PSC-833 clearance was observed between patients who did and did not receive dexamethasone (0.26\(\pm\)0.11 liter/h/kg vs. 0.28\(\pm\)0.08 liter/h/kg).

**Pharmacodynamics** There was a negative sigmoidal relationship with large variability between the surviving fraction of neutrophils and the AUC of doxorubicin (Fig. 3). Although neutropenia was dose limiting at 50 mg/m\(^2\) of doxorubicin, which was lower than the conventional dose without PSC-833, the pharmacodynamic relationship between the doxorubicin AUC and neutropenia was not altered by combination with PSC-833. Comparison of neutropenia in the control patients who were treated with doxorubicin as a single agent to that in patients treated with doxorubicin and PSC-833 showed no difference in distribution.

### Table VI. Pharmacokinetic Parameters of PSC-833

| Dose level | No. patients | PSC-833  | Pharmacokinetic parameters |
|-----------|--------------|---------|-----------------------------|
|           |              | LD\(^a\) (mg/kg) | CD\(^b\) (mg/kg) | \(C_{\text{max}}\)\(^c\) (ng/ml) | AUC\(^d\) (ng×h/ml) | \(C_{\text{ss}}\)\(^e\) (ng/ml) | Clearance (liter/h/kg) |
| I         | 4            | 1       | 1   | 1288\(\pm\)589 | 7.8\(\pm\)4.1 | 190\(\pm\)104 | 0.28\(\pm\)0.15 |
| II        | 3            | 1       | 2   | 1088\(\pm\)359 | 26.7\(\pm\)11.6 | 474\(\pm\)96 | 0.18\(\pm\)0.03 |
| III       | 3            | 2       | 4   | 2331\(\pm\)638 | 36.0\(\pm\)9.8 | 688\(\pm\)107 | 0.25\(\pm\)0.04 |
| IV        | 6            | 2       | 6   | 2174\(\pm\)652 | 53.2\(\pm\)16.6 | 1147\(\pm\)328 | 0.24\(\pm\)0.08 |
| V         | 7            | 2       | 8   | 1734\(\pm\)575 | 54.7\(\pm\)19.3 | 1277\(\pm\)434 | 0.29\(\pm\)0.11 |
| VI–VIII   | 8            | 2       | 10  | 2495\(\pm\)1311 | 58.2\(\pm\)14.8 | 1383\(\pm\)352 | 0.32\(\pm\)0.08 |

Parameters are mean value\(\pm\)SD. 
\(a\) LD, loading dose; \(b\) CD, continuous dose; \(c\) \(C_{\text{max}}\), the maximum concentration; \(d\) AUC\(^e\), area under the concentration-time curve to the last measured point; \(e\) \(C_{\text{ss}}\), steady-state concentration.
bution in the scatterplot between the AUC of doxorubicin vs. the surviving fraction of neutrophils (Fig. 3). Similarly, there was no difference in the pharmacodynamic relationship according to the concentration of PSC-833.

Bioassay The activity of patients’ serum for reversing the resistance to doxorubicin of the P-glycoprotein-expressing 8226/Dox6 cell line was investigated when sufficient samples were obtained. In the patients’ serum before the administration of PSC-833, the median IC50 of the sensitive parent cell line, 8226S, was 0.5 µg/ml (0.2–1.4 µg/ml, n=28), while the median IC50 of the resistant cell line, 8226/Dox6, was 5.9 µg/ml (1.2–19.3 µg/ml, n=28). The sensitivity of 8226/Dox6 was increased to a median IC50 of 1.3 µg/ml (0.2–8.3 µg/ml, n=26) when patients’ serum at the time of doxorubicin administration and during PSC-833 infusion was used (P<0.0001 by Wilcoxon signed-rank test, n=24). The increased sensitivity was maintained to the end of the PSC-833 infusion, at which point the median IC50 was 1.1 µg/ml (0.4–7.8 µg/ml, n=28). The IC50 value of doxorubicin in 8226/Dox6 cells ranged from 1.2 to 19.3 µg/ml, suggesting that the IC50 value would vary from patient to patient. To correct the interpatient variability of the IC50 before treatment, a dose-modifying factor was calculated for each patient by dividing the IC50 in the serum before the PSC-833 infusion by the IC50 during the infusion. The dose modifying factor at the time of doxorubicin administration ranged from 1.0 to 68.2 (median 4.6, n=24). These values were unchanged at the end of the PSC-833 infusion (median 4.7, range 0.9–29.1, n=25, Fig. 4).

One partial response was observed at the highest dose level in a patient with ovarian cancer who had received doxorubicin prior to entry into this study.

DISCUSSION

This study showed that PSC-833 could be administered in combination with doxorubicin with acceptable toxicity. Neutropenia was dose limiting when the dose of doxorubicin was increased to 50 mg/m². The only clinically significant toxicity attributable to PSC-833 was grade 3 ataxia observed in a patient treated at the highest dosage. Isolated hyperbilirubinemia was observed throughout the dose escalation but was transient and clinically insignificant in all but one patient who had carcinoma of the ampulla of Vater and died from biliary infection complicated with grade 4 neutropenia. These toxicity profiles were in accordance with other studies of PSC-833 in combination with doxorubicin or other anticancer agents in which observed toxicities were essentially those of anticancer agents and in which neurological toxicities were observed only at very high dosages. The inhibitory action of PSC-833 on hepatocyte transporters may be the principal mechanism for the hyperbilirubinemia. Bilirubin is excreted into bile from hepatocytes via membrane transporters which include multidrug resistance protein 2 (MRP2) and PSC-833 was reported to inhibit not only P-glycoprotein, but also MRP2. Also, in previous reports, the inhibition of the transporters by PSC-833 and cyclosporin resulted in hyperbilirubinemia. Similarly, the inhibitory action of PSC-833 on P-glycoprotein, which plays a key role as the blood-brain barrier, may explain the ataxia noted in this and other studies. This also might be
related to the observation in this study that the severity of emetic reactions to the combination of doxorubicin and PSC-833 was more than that to doxorubicin as a single agent without PSC-833 or in combination with other anticancer agents.

A decrease in the ejection fraction was observed in a patient after two courses of treatment, although it resulted in no symptoms and was clinically insignificant. He had not been treated with anthracyclines before entry into this study. The cumulative dose of doxorubicin was 60 mg/m² when the decrease of ejection fraction developed, suggesting that the combination of doxorubicin with PSC-833 might increase the cardiotoxicity of doxorubicin. Enhanced cardiotoxicity of doxorubicin as a result of P-glycoprotein modulation was suggested because the inhibition of P-glycoprotein function in mice by either the disruption of the mdr1a gene or the administration of PSC-833 increased the accumulation of doxorubicin and its cardiotoxic metabolite, doxorubicinol, in the heart.40, 41) Cardiac functions in patients treated with PSC-833 did increase the serum from patients treated with PSC-833. Although the expression of MRP2 or other transporters in the doxorubicin-resistant cell line was not extensively investigated, we believe that the inhibition of P-glycoprotein by PSC-833 was the main mechanism of reversal of the resistance to doxorubicin.

To seek pharmacokinetic interaction between doxorubicin and PSC-833, pharmacokinetic data for doxorubicin in combination with PSC-833 were compared to those of doxorubicin administered without PSC-833. The co-administration of PSC-833 decreased the systemic clearance of doxorubicin by 50%. Although this was not a crossover study, we selected control patients who fulfilled the eligibility criteria of this study with regard to age, PS, hepatic and renal function. There was no difference in these variables, as well as in sex, weight and body surface area, between the patients treated in this phase I study and the control patients (data not shown). Furthermore, the administration schedule of doxorubicin was the same in the two groups. Therefore, we believe that the control data were comparable to the data obtained in this study. A decrease in the clearance and an increase in the AUC of doxorubicin and other anticancer agents by the co-administration of PSC-833 also have been documented in other studies.22–24, 26) P-Glycoprotein and other transporters are found at the biliary canalicular membrane of hepatocytes and excrete xenobiotics, and the inhibition of excretory pumps by PSC-833 may be the principal mechanism for the pharmacokinetic interaction.44)

The recommended doxorubicin dose in combination with PSC-833 in this study was 40 mg/m², which was half of the conventional dose.45) This was in accordance with the results of a dose-finding study of orally administered PSC-833 and doxorubicin where the doxorubicin dose was decreased to 35 mg/m².22) P-Glycoprotein is also expressed in hematopoietic stem cells, and the possible potentiation of myelosuppression by PSC-833 had been a concern.46) However, the reduction of the dosage of doxorubicin appears to result from the pharmacokinetic interaction between doxorubicin and PSC-833, not from the increased sensitivity of hematopoietic cells to doxorubicin. The combination with PSC-833 doubled the AUC of doxorubicin in this study and another study.26) The 50% reduction of the doxorubicin dose corresponded to the change in the doxorubicin AUC in combination with PSC-833. Furthermore, the pharmacodynamic relationship between doxorubicin AUC and neutropenia was not changed by combination with PSC-833 (Fig. 3). The extent of neutropenia was not increased, as the concentration of PSC-833 was increased when the AUC of doxorubicin was taken into account.

Altered doxorubicin pharmacokinetics, increased central nervous system toxicities, and augmented emetic reactions indicated that pharmacological activity of PSC-833 could be achieved in patients. However, clinical benefits of PSC-833 depend on the selectivity of modulation. The extent of modulation in tumors should be greater than that in normal tissues. In recent preliminary reports of randomized trials, PSC-833 failed to improve complete remission rates or survival when used in combination chemotherapy against
leukemia. Further clinical studies should be conducted to determine if PSC-833 overcomes the drug resistance of other cancers or when used in other regimens.

In conclusion, PSC-833 at 2 and 10 mg/kg for the loading dose and the continuous dose, respectively, was safely tolerated dose and the continuous dose, respectively, was safely tolerated. Activity to reverse the resistance to doxorubicin was achieved in patients’ serum at those doses of PSC-833. Because the addition of PSC-833 doubled the AUC of doxorubicin, the dosage of doxorubicin should be reduced accordingly, but no augmentation of neutropenia was observed when the change in doxorubicin pharmacokinetics was considered.

ACKNOWLEDGMENTS

This work was supported in part by a Grant-in-Aid for Cancer Research from the Ministry of Health and Welfare, Japan, and by Novartis Pharma K.K., Japan.

(Received September 4, 2000/Revised November 15, 2000/Accepted November 17, 2000)

REFERENCES

1) Pastan, I. and Gottesman, M. Multiple-drug resistance in human cancer. *N. Engl. J. Med.*, **316**, 1388–1393 (1987).
2) Fisher, G. A., Lum, B. L., Hausdorff, J. and Sicic, B. I. Pharmacological considerations in the modulation of multidrug resistance. *Eur. J. Cancer*, **32A**, 1082–1088 (1996).
3) Chu, X.-Y., Kato, Y. and Sugiyama, Y. Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats. *Drug Metab. Dispos.*, **27**, 440–441 (1999).
4) Foj, A. T., Ueda, K., Slamon, D. J., Poplack, D. G., Gottesman, M. M. and Pastan, I. Expression of a multidrug-resistance gene in human tumors and tissues. *Proc. Natl. Acad. Sci. USA*, **84**, 265–269 (1987).
5) Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I. and Willingham, M. C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. *Proc. Natl. Acad. Sci. USA*, **84**, 7735–7738 (1987).
6) Cordon-Cardo, C., O’Brien, J. P., Casals, D., Rittman-Grauer, L., Biedler, J. L., Melamed, M. R. and Bertino, J. R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. *Proc. Natl. Acad. Sci. USA*, **86**, 695–698 (1989).
7) Kusuhara, H., Suzuki, H., Terasaki, T., Kakee, A., Lemaire, M. and Sugiyama, Y. P-Glycoprotein mediates the efflux of quinidine across the blood-brain barrier. *J. Pharmacol. Exp. Ther.*, **283**, 574–580 (1997).
8) Tsuruo, T., Iida, H., Tsukagoshi, S. and Sakurai, Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. *Cancer Res.*, **41**, 1967–1972 (1981).
9) Tsuruo, T., Iida, H., Nojiri, M., Tsukagoshi, S. and Sakurai, Y. Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers. *Cancer Res.*, **43**, 2905–2910 (1983).
10) Tsuruo, T., Iida, H., Kitatani, Y., Yokota, K., Tsukagoshi, S. and Sakurai, Y. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells. *Cancer Res.*, **44**, 4303–4307 (1984).
11) Chauffert, B., Pelletier, H., Corda, C., Solary, E., Bedenne, L., Caillot, D. and Martin, F. Potential usefulness of quinidine to circumvent the anthracycline resistance in clinical practice. *Br. J. Cancer*, **62**, 395–397 (1990).
12) Sonneveld, P., Durie, B. G. M., Lokhorst, H. M., Marie, J.-P., Solbu, G., Suciu, S., Zittoun, R., Lowenberg, B. and Noorder, K. Modulation of multidrug-resistant multiple myeloma by cyclosporin. *Lancer*, **340**, 255–259 (1992).
13) Foster, B. J., Grotzinger, K. R., McKoy, W. M., Rubinstein, L. V. and Hamilton, T. C. Modulation of induced resistance to adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleate. *Cancer Chemother. Pharmacol.*, **22**, 147–152 (1988).
14) DeGregorio, M. W., Ford, J. M., Benz, C. J. and Wiebe, V. I. Toremifène: pharmacologic and pharmacokinetic basis of reversing multidrug resistance. *J. Clin. Oncol.*, **7**, 1359–1364 (1989).
15) Ozols, R. F., Cunnion, R. E., Raymond, W., Klecker, J., Hamilton, T. C., Ostchega, Y., Parrillo, J. E. and Young, R. C. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. *J. Clin. Oncol.*, **5**, 641–647 (1987).
16) Dalton, W. S., Crowley, J. J., Salmon, S. S., Grogan, T. M., Laufman, L. R., Weiss, G. R. and Bonnet, J. D. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. *Cancer*, **75**, 815–820 (1995).
17) Wilson, W. H., Jamis-Dow, C., Bryant, G., Balis, F. M., Klecker, R. W., Bates, S. E., Chabner, B. A., Steinberg, S. M., Kohler, D. R. and Wittes, R. E. Phase I and pharmacokinetic study of the multidrug resistance modulator dextramycin with EPOCH chemotherapy. *J. Clin. Oncol.*, **13**, 1985–1994 (1995).
18) Samuels, B. L., Mick, R., Vogelzang, N. J., Williams, S. F., Schilsky, R. L., Safa, A. R., O’Brien, S. M. and Ratain, M. J. Modulation of vinblastine resistance with cyclosporine: a phase I study. *Clin. Pharmacol. Ther.*, **54**, 421–429 (1993).
19) List, A. F., Spier, C., Greer, J., Wolff, S., Hutter, J., Dorr, R., Salmon, S., Futscher, B., Baier, M. and Dalton, W. Phase I/II trial of cyclosporin as a chemotherapy-resistance modifier in acute leukemia. *J. Clin. Oncol.*, **11**, 1652–1660 (1993).
20) Gavieraux, C., Boesch, D., Jachez, B., Bollinger, P., Payne,
T. and Loor, F.  SDZ PSC 833, a non-immunosuppressive cyclosporin analog, is a very potent multidrug-resistance modifier.  *J. Cell. Pharmacol.*, 2, 225–234 (1991).

21) Watanabe, T., Tsuge, H., Oh-hara, T., Naito, M. and Tsuruo, T.  Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance *in vitro* and *in vivo*.  *Acta Oncol.*, 34, 235–241 (1995).

22) Giaccone, G., Linn, S. C., Welink, J., Catimel, G., Stieljes, H., van der Vijgh, W. J. F., Eeltink, C., Vermorken, J. B. and Pinedo, H. M.  A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors.  *Clin. Cancer Res.*, 3, 2005–2015 (1997).

23) Kornblau, S. M., Estey, E., Madden, T., Tran, H. T., Zhao, S., Consoli, U., Snell, V., Sanchez-Williams, G., Kantarjian, H., Keating, M., Newman, R. A. and Andreeff, M.  Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia.  *J. Clin. Oncol.*, 15, 1796–1802 (1997).

24) Boote, D. J., Dennis, I. F., Twentyman, P. R., Osborne, R. J., Laburte, C., Hensley, S., Smyth, J. F., Brampton, M. H. and Bleehen, N. W.  Phase I Study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer.  *J. Clin. Oncol.*, 14, 610–618 (1996).

25) Lee, E. J., George, S. L., Caligiuri, M., Szatrowski, T. P., Powell, B. L., Lemke, S., Dodge, R. K., Smith, R., Baer, M. and Schiffer, C. A.  Parallel phase I study of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of Cancer and Leukemia Group B study 9420.  *J. Clin. Oncol.*, 17, 2831–2839 (1999).

26) Sonneveld, P., Marie, J.-F., Huismans, C., Vekhoff, A., Schooeter, M., Fauss, A. M., van Kapel, J., Groenewegen, A., Charneck, S., Zitoun, R. and Löwenberg, B.  Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma: a phase I study.  *Leukemia*, 10, 1741–1750 (1996).

27) Fischer, V., Rodriguez-Gascon, A., Heitz, F., Taynes, R., Hauck, C., Cohen, D. and Vickers, A. E. M.  The multidrug resistance modulator valsparod (PSC 833) is metabolized by human cytochrome P450 3A.  *Drugs Metab. Dispos.*, 26, 802–811 (1998).

28) Nakajima, O., Immamura, Y., Matsumoto, A., Koyama, Y., Shomura, T., Kawamura, K. and Murata, S.  Comparative studies on the pharmacokinetics between THP and Adriamycin in the same patients.  *Jpn. J. Cancer Chemother.*, 13, 261–270 (1986).

29) Dalton, W. S., Durie, B. G. M., Alberts, D. S., Gerlach, J. H. and Cress, A. E.  Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein.  *Cancer Res.*, 46, 5125–5130 (1986).

30) Dalton, W. S., Grogan, T. M., Rybski, J. A., Scheper, R. J., Richter, L., Kailey, J., Broxterman, H. J., Pinedo, H. M. and Salmon, S. E.  Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation.  *Blood*, 73, 747–752 (1989).

31) Oude-Ellerink, R. P., Meijer, D. K., Kuipers, F., Jansen, P. L., Groen, A. K. and Groothuis, G. M.  Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport.  *Biochim. Biophys. Acta*, 17, 215–268 (1995).

32) Jedlitschky, G., Leier, I., Buchholz, U., Hummel-Eisenbeiss, J., Burchell, B. and Keppler, D.  ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRPI and its hepatocyte canalicular isoform MRP2.  *Biochem. J.*, 327 (Pt 1), 305–310 (1997).

33) Aszalos, A., Thompson, K., Yin, J.-J. and Ross, D. D.  Combination of P-glycoprotein blockers, verapamil, PSC833, and Cremophor act differently on the multidrug resistance associated protein (MRP) and on P-glycoprotein (Pgp).  *Anticancer Res.*, 19, 1053–1064 (1999).

34) Chen, Z.-S., Kawabe, T., Ono, M., Aoki, S., Sumizawa, T., Furukawa, T., Uchiumi, T., Wada, M., Kuwano, M. and Akiyama, S.-I.  Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multi-specific organic anion transporter.  *Mol. Pharmacol.*, 56, 1219–1228 (1999).

35) Bohme, M., Buchler, M., Muller, M. and Keppler, D.  Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane.  *FEBS Lett.*, 333, 193–196 (1993).

36) Schinkel, A. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M. and Borst, P.  Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.  *J. Clin. Invest.*, 96, 1698–1705 (1995).

37) Lemaire, M., Bruelisauer, A., Guntz, P. and Sato, H.  Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin, in rats.  *Cancer Chemother. Pharmacol.*, 38, 481–486 (1996).

38) Mayer, U., Wagenaar, E., Dorobek, B., Beijnen, J. H., Borst, P. and Schinkel, A. H.  Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoproteins by oral treatment of mice with PSC833.  *J. Clin. Invest.*, 100, 2430–2436 (1997).

39) Desrayaud, S., Lange, E. C. M. D., Lemaire, M., Bruelisauer, A., Boer, A. G. D. and Breimer, D. D.  Effect of the mdr1a P-glycoprotein gene disruption on the tissue distribution of SDZ PSC 833, a multidrug resistance-reversing agent, in mice.  *J. Pharmacol. Exp. Ther.*, 285, 438–443 (1998).

40) van Asperen, J., van Tellingen, O., Tijsen, F., Schinkel, A. H. and Beijnen, J. H.  Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein.  *Br. J. Cancer*, 79, 108–113 (1999).

41) Gonzalez, O., Colombo, T., Fusco, M. D., Imperatori, L., Zucchetti, M. and D’Incalci, M.  Changes in doxorubicin distribution and toxicity in mice pretreated with the...
cyclosporin analogue SDZ PSC 833. Cancer Chemother. Pharmacol., 36, 335–340 (1995).
42) Simon, N., Dailly, E., Combes, O., Malaurie, E., Lemaire, M., Tillement, J.-P. and Urien, S. Role of lipoprotein in the plasma binding of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin. Br. J. Clin. Pharmacol., 45, 173–175 (1998).
43) Smith, A. J., Mayer, U., Schinkel, A. H. and Borst, P. Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum. J. Natl. Cancer Inst., 90, 1161–1166 (1998).
44) Speeg, K. V. and Maldonado, A. L. Effect of the nonimmunosuppressive cyclosporin analog SDZ PSC-833 on colchicine and doxorubicin biliary secretion by the rat in vivo. Cancer Chemother. Pharmacol., 34, 133–136 (1994).
45) Edmonson, J. H., Ryan, L. M., Blum, R. H., Brooks, J. S., Shiraki, M., Frytak, S. and Parkinson, D. R. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J. Clin. Oncol., 11, 1269–1275 (1993).
46) Chaudhary, P. M. and Roninson, I. B. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell, 66, 85–94 (1991).
47) Greenberg, P., Advani, R., Tallman, M., Letendre, L., Saba, H., Dugan, K., Lee, S. J., Lum, B., Sikic, B. I., Paietta, E., Bennett, J. and Rowe, J. M. Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs MEC: randomized phase III trial (E2995). Blood, 94 (Suppl. 1), 383a (1999).
48) Baer, M. R., George, S. L., Dodge, R. K., Cooke, K., Caligiuri, M. A., Powell, B. L., Kolitz, J. E., Schiffer, C. A. and Larson, R. A. Phase III study of PSC-833 modulation of multidrug resistance (MDR) in previously untreated acute myeloid leukemia (AML) patients ≥60 years (CALGB 9720). Blood, 94 (Suppl. 1), 383a (1999).